[Pharmaco-dynamic influence under ascites or laparotomy on intraperitoneal sequential MTX/5-FU therapy].
We studied pharmaco-dynamic changes of intraperitoneal sequential MTX (30 mg)/5-FU (750 mg) therapy in gastric cancer patients with malignant ascites and those who had undergone a gastrectomy. The serum and ascites levels of MTX in patients with malignant ascites decreased much slower than in patients without ascites. In patients with ascites, the serum MTX concentration peaked 8 hours later and then gradually decreased. The ascites MTX level decreased as low as 1/10 2 days after the intraperitoneal administration. The serum and ascites 5-FU levels revealed a minor prolongation of 5-FU concentration in patients with ascites. Gastrectomy did not affect the pharmaco-dynamics of MTX in post-operative patients with sequential intraperitoneal administration of MTX/5-FU on 1, 8 and 15 POD.
Dept. of Surgery, Tokyo Metropolitan Ohkubo Hospital.
M
M
Maruyama
T
T
Irie
T
T
Yoshida
T
T
Nagahama
N
N
Sugano
M
M
Ebuchi
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001202:Ascitic Fluid / Q000378:metabolism*; D005472:Fluorouracil / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D005743:Gastrectomy; D006801:Humans; D007263:Infusions, Parenteral; D008727:Methotrexate / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D010534:Peritoneal Neoplasms / Q000556:secondary; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology
D005472:Fluorouracil; D008727:Methotrexate